EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Biomimetic delivery systems for overcoming drug resistance in gastrointestinal cancers

Gou Wu, Ai-Xue Li, Yong-Wei Gu, Xiao-Li Cheng, Rong-Chen Mao, Xue-Jun Wang, Meng-Yuan He, Qing-Qing Chai, Feng-Na Li, Hai-Yue Liu, Wen-Xin Zhang, Xin-Yi Zheng und 3 weitere

Drug Resistance Updates · 2026

DOI: 10.1016/j.drup.2026.101465 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Drug Resistance Updates, 2026. Verfasst von Gou Wu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China. Hauptthemen laut MEDLINE: Drug Resistance, Neoplasm, Gastrointestinal Neoplasms, Antineoplastic Agents, Biomimetics. Die Arbeit nennt 192 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Commission of Shanghai Municipality.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gastrointestinal (GI) cancers remain a major cause of cancer-related mortality worldwide, and multidrug resistance (MDR) is a critical barrier to durable therapeutic response. In GI malignancies, MDR arises from multilayered and interdependent factors, including insufficient intracellular drug accumulation, altered drug activation and metabolic detoxification, target rewiring and phenotypic plasticity, apoptosis-autophagy-mediated stress adaptation, and extrinsic protection from the tumor microenvironment, cancer stem cells, metastatic niches, and microbiome-associated mechanisms. Biomimetic delivery systems (BDSs), including cell membrane-coated nanocarriers, extracellular vesicles, and living or virus-mediated platforms, provide biological interface functions that may improve drug circulation, tumor recognition, tissue penetration, membrane interaction, and active trafficking. However, their therapeutic value in MDR GI cancers should not be judged merely by improved delivery efficiency, but by whether they address defined resistance bottlenecks and generate evidence of genuine re-sensitization in resistant disease contexts. Current evidence indicates that many BDSs remain at the level of exposure enhancement or mechanism-aligned sensitization, whereas only a limited subset has demonstrated functional restoration of treatment response in established resistant models. This review organizes current BDS strategies according to their dominant mechanistic functions: enhancing drug accumulation and intratumoral delivery, reversing cellular drug resistance, remodeling resistance-supportive tumor microenvironment, targeting cancer stem cells (CSCs) and metastatic niches, and enabling site-directed intervention using living carriers and living therapeutics. By linking GI cancer-focused MDR biology to function-oriented biomimetic design, this review establishes an evidence-based framework for distinguishing delivery enhancement from true MDR reversal and outlines platform-specific requirements for clinical translation.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug Resistance, NeoplasmGastrointestinal NeoplasmsAntineoplastic AgentsBiomimeticsDrug Delivery SystemsBiomimetic MaterialsHumansTumor MicroenvironmentDrug Resistance, MultipleAnimalsNeoplastic Stem CellsDrug Carriers

Stichwörter der Autor:innen

Biomimetic delivery systemsGastrointestinal cancersMechanism-oriented deliveryMultidrug resistanceTumor microenvironment

Substanzen

Antineoplastic AgentsDrug Carriers

Autor:innen und Institutionen

  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China.
  • Department of Pharmacy, Fudan University Shanghai Cancer Center, Fudan University, Shanghai 200032, China.
  • College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China.
  • School of Pharmacy, Faculty of Medicine, Macau University of Science and Technology, 999078, Macao Special Administrative Region of China.
  • Department of Pharmacy, Huashan Hospital, Fudan University, Shanghai 200040, China. Electronic address: zwu14@fudan.edu.cn.
  • College of Pharmacy, Shandong University of Traditional Chinese Medicine, Jinan 250355, China. Electronic address: wuxin007@126.com.

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Commission of Shanghai Municipality

Zitieren

APA

Wu, G., Li, A. X., Gu, Y. W., Cheng, X. L., Mao, R. C., Wang, X. J., He, M. Y., Chai, Q. Q., Li, F. N., Liu, H. Y., Zhang, W. X., Zheng, X. Y., Wu, Z., Wu, X., & Liu, J. Y. (2026). Biomimetic delivery systems for overcoming drug resistance in gastrointestinal cancers. Drug Resistance Updates. https://doi.org/10.1016/j.drup.2026.101465

Vancouver

Wu G, Li AX, Gu YW, Cheng XL, Mao RC, Wang XJ, et al. Biomimetic delivery systems for overcoming drug resistance in gastrointestinal cancers. Drug Resistance Updates. 2026. doi:10.1016/j.drup.2026.101465

BibTeX
@article{Wu2026,
  author = {Wu, Gou and Li, Ai-Xue and Gu, Yong-Wei and Cheng, Xiao-Li and Mao, Rong-Chen and Wang, Xue-Jun and He, Meng-Yuan and Chai, Qing-Qing and Li, Feng-Na and Liu, Hai-Yue and Zhang, Wen-Xin and Zheng, Xin-Yi and Wu, Zhuo and Wu, Xin and Liu, Ji-Yong},
  title = {Biomimetic delivery systems for overcoming drug resistance in gastrointestinal cancers},
  journal = {Drug Resistance Updates},
  year = {2026},
  doi = {10.1016/j.drup.2026.101465}
}
Kostenlos starten →